Atorvastatin and all five metabolites were eluted within 4 min.
Quantification was performed through positive ion electrospray ionization (ESI).
Atorvastatin and other drugs from the statin class of medications including lovastatin, pravastatin, rosuvastatin, fluvastatin, and simvastatin are considered first-line options for the treatment of dyslipidemia.
Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world.
Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.
While all statin medications are considered equally effective from a clinical standpoint, rosuvastatin is considered the most potent; doses of 10 to 40mg rosuvastatin per day were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while atorvastatin has been found to have about one-third of that potency.
In relation to renal function, atorvastatin was the safest statin as it resulted in the least number of patients at the end of 2 years of treatment with the new onset of microalbuminuria (10.9%) followed by rosuvastatin (14.3%) and then pravastatin (26.6%). In the Qatari context, the most effective statin at reducing LDL-C was rosuvastatin 10 mg.
Atorvastatin was the safest statin in relation to renal function.
Medical Research Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangdong Cardiovascular Institute, 106 Zhongshan Road, Weilun Bldg.